Top Biotech Companies in Bengaluru (62)
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.
Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.
Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.
Pandorum is a biotechnology company based out of the US and India, working in the field of Tissue Engineering and Regenerative Medicine. With its distinct synergy of life science, engineering and clinical competences, at Pandorum, we have developed a proprietary technology platform which combines therapeutic exosomes with anti-inflammatory, anti-fibrotic properties derived from clinical grade human stem cells and biomaterials with...
Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products’ development and manufacturing.
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel’s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are...
Cytel's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Private-equity ownership by Astorg and Nordic Capital is positioned as support to accelerate Cytel’s next phase of growth and innovation, signaling access to growth-oriented capital and sponsorship.
Product Line Growth: East Horizon launched as a cloud-based evolution of Cytel’s trial-design software and has continued adding modules through 2025, indicating ongoing investment and expansion of the software offering.
Market Expansion: Multiple acquisitions in 2022–2023 (e.g., Stève Consultants and co.faktor) and an increase in offices from 2021 to 2023 indicate broader geographic coverage and capability expansion, particularly across Europe.
Sitero is a next-generation, site-focused clinical research organization (CRO) for life sciences and institutional research organizations that helps get treatments to market safer and faster through tech-forward services that streamline research. Accelerate your clinical trial, drive compliance and safety, and unlock innovation with access to powerful technology and world-class services. Sitero combines the expertise of a tenured team with a...
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve...
Avantor's Top Stability & Growth Strengths
Strong Market Position & Advantage: Disclosures describe one of the two largest global lab distributors via VWR with broad reach into research and production labs worldwide and deep embedment in biopharma workflows. This positions the company as a top-tier player in lab distribution and life-science consumables even if not the overall market leader.
Healthy Cash Flow: Recent updates highlight strong free-cash-flow conversion and deleveraging exiting 2024. Management emphasized ongoing cash generation alongside margin improvement.
Cost & Operational Efficiency: Management is executing multi-year cost programs with margin improvement evident in late 2024. Efficiency actions and portfolio focus are intended to support profitability despite uneven demand.
Enzene Biosciences Ltd is a technology driven Biotech Company based out of Pune, India. We strive to harness disruptive innovation to enhance global healthcare. Enzene is in business of Biosimlilars, Phytopharma, Peptide and Regenerative Business. Enzene has following centres: R&D Centre : The R&D centre in Bhosari, Pune has technical expertise in terms of talent and infrastructure to access biosimilar market in domestic...
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer. We have a legacy of over three decades and trace our origins to the API expertise of Strides Shasun Ltd. and the technical knowhow of human API business from Sequent Scientific Ltd. We are poised to bridge the industry gap by delivering value based products while...
Strides Pharma Inc. is the US-based business of Strides Pharma Science Limited, dedicated to providing quality healthcare products and affordable generic medicines. The company specializes in manufacturing various dosage forms, including soft-gel capsules, oral solids, modified releases, topicals, and liquids.
BrightInsight provides the leading global platform for biopharma and medtech regulated digital health solutions. We are the launch partner companies trust to accelerate time to market for regulated digital health products including apps, algorithms, medical devices, connected combination products, companion diagnostics, and Software as a Medical Device (SaMD). BrightInsight replaces the need for lengthy and complex ‘build from scratch’ implementations....
We perform Antibody Discovery using Artificial Intelligence. Job Openings: https://www.immunitoai.com/job-openings Our Team: https://www.immunitoai.com/about-us YouTube Channel: https://www.youtube.com/@immunitoAI
Biofourmis is a fast-growing digital health company filled with committed, passionate people who care about augmenting personalized care and empowering people with complex chronic conditions to live better and healthier lives. We are pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and...
A pioneering clinical stage startup company leading the Cell & Gene therapy revolution and are committed to bringing breakthrough cancer treatment to patients in India, making it accessible & affordable.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our...
Lupin is a global pharmaceutical company offering Branded and Generic Formulations, Biosimilars and Active Pharmaceutical Ingredients (APIs). Founded over 50 years ago, Lupin today is a significant player in the US, India and Japan and additionally in other counties within APAC, EMEA and LATAM. It holds a global leadership position in Anti-TB and Cephalosporin segments. Today Lupin is focused on...
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...
Endpoint Clinical, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly characterized as a global leader in RTSM/IRT with substantial operating scale, supporting 2,000+ studies across 90+ countries and 800+ active studies. This breadth and ability to handle complex, global trials provide a durable competitive edge.
Investor Backing & Capital Strength: The June 2024 acquisition by Arsenal Capital Partners supplies focused capital and sponsor support to accelerate expansion and innovation. This backing is presented as validation of market position and a catalyst for the next phase of growth.
Innovation-Driven Growth: Five generations of purpose-built RTSM platforms and the proprietary PULSE platform, including faster study builds in four weeks or less, indicate sustained product advancement. A 2025 brand refresh and continued tech investment underscore a roadmap aimed at pushing RTSM forward.
